- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06673160
Pumping to Up Maternal Milk Production for Preterms (PUMMPP)
Pumping to Up Maternal Milk Production for Preterms (PUMMPP)
The goal of this clinical trial is to learn about the effect of breast-pumping frequency on breast milk supply/ volume in mothers of preterm infants. The main question it aims to answer is:
- What effect does pumping frequency have on breast milk supply.
Researchers will compare breastmilk supply of mothers who pump every 2 hours to the supply of those who pump every 3 hours to see if there is a difference in the amount of breastmilk they produce.
Participants will be assigned to either pump every 2 hours or every 3 hours and record how many milliliters of breastmilk they produce daily for the first 28 days of their baby's life.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Folasade Aderibigbe, MD
- Phone Number: 205-934-8793
- Email: Sade.Aderibigbe72@gmail.com
Study Contact Backup
- Name: Colm Travers, MD
- Phone Number: 205-934-8793
- Email: cptravers@uabmc.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- Recruiting
- University of Alabama Birmingham
-
Contact:
- Colm Travers, MD
- Phone Number: 205-934-4680
- Email: cptravers@uabmc.edu
-
Contact:
- Folasade Aderibigbe, MD
- Phone Number: 205-934-4680
- Email: fmaderibigbe@uabmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Inborn infants <32 weeks gestation
- Out-born infants transferred to our facility <48hours of life
- Infants <1500 grams at birth
- Infants whose parents/ guardians have provided legal consent for study participation
Exclusion Criteria:
- Infants with birthing persons' that are severe/critically ill
- Birthing persons of infants <18 years old
- Infants with terminal illness or decision to withhold or limit support
- infants with major congenital anomalies, chromosomal disorders, or congenital infections
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pumping every 2 hours
Mothers of patients in this group will be assigned to pump/ express breastmilk every 2 hours.
|
The intervention will be pumping every 2 hours.
Other Names:
|
|
Active Comparator: Pumping every 3 hours
Mothers of patients in this group will be assigned to pump/ express breastmilk every 3 hours.
|
The intervention will be pumping every 3 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Volume of expressed breastmilk
Time Frame: From enrollment to 28 days of life
|
The primary outcome measure will be the volume of expressed breastmilk obtained in mL per day in the group pumping every 2 hours compared the group pumping every 3 hours
|
From enrollment to 28 days of life
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The percentage of donor breast milk feedings
Time Frame: From enrollment to 28 days of life
|
This outcome will assess the percentage of any enteral feeding that is derived from donor breast milk.
|
From enrollment to 28 days of life
|
|
The number of days alive on full feedings
Time Frame: From enrollment to 28 days of life
|
The total number of days the infant received full enteral feeds (≥120 milliliters(mL)/kilogram(kg)/day).
|
From enrollment to 28 days of life
|
|
The time to full feedings
Time Frame: From enrollment to 28 days of life
|
The number of days it takes to initially reach full enteral feeds (≥120mL/kg/day)
|
From enrollment to 28 days of life
|
|
The number of infants with clinical evidence of feeding intolerance
Time Frame: From enrollment to first 28 days after birth
|
Infants that have enteral feeds withheld, or in other words made "nothing by mouth" (NPO) > 24 hours for feeding or abdominal issues
|
From enrollment to first 28 days after birth
|
|
Number of central line days
Time Frame: In the first 28 days of life
|
The total number of days the infant maintained any type of central line access.
|
In the first 28 days of life
|
|
The number of infants receiving any volume of breastmilk at time of discharge
Time Frame: From enrollment to hospital discharge
|
Infants who are still receiving any volume of expressed breastmilk upon discharge will be identified and noted.
|
From enrollment to hospital discharge
|
|
The number of infants exclusively feeding breastmilk at discharge
Time Frame: From enrollment to hospital discharge
|
Whether or not enrolled infants are receiving all their nutrition from their mom's own expressed breastmilk upon discharge will be noted
|
From enrollment to hospital discharge
|
|
Average change in weight
Time Frame: from birth to 36 weeks' corrected gestational age
|
Changes in weight measured in grams (g) from birth to 36 weeks corrected gestational age
|
from birth to 36 weeks' corrected gestational age
|
|
Average change in length
Time Frame: from birth to 36 weeks corrected gestational age
|
Changes in length measured in centimeters (cm)
|
from birth to 36 weeks corrected gestational age
|
|
Average change in head circumference
Time Frame: from birth to 36 weeks' corrected gestational age
|
Change in head circumference measured in centimeters (cm)
|
from birth to 36 weeks' corrected gestational age
|
|
The Bayley Scales of Infant and Toddler Development (BSID)
Time Frame: from 18-26 months of age
|
The Bayley's cognitive component composite score will be assessed and noted. The cognitive composite score is determined by comparing the child's performance to a normative age-matched sample defined by the assessment. They are interpreted as follows: Mean score of 100 (Standard deviation=15) at the 50th percentile signifies mid-average functioning. Scores below 85 (1 Standard deviation below the mean), at the 16th percentile, indicate mild impairment of being 'at risk' of developmental delay. Monitoring is recommended, along with advice to parents on techniques to enhance development or referral to a therapist based on the level of impairment. Score below 70 (2 Standard deviation below the mean), at the second percentile, indicate moderate to severe impairment. In general, scores falling in the lowest 10th percentile indicate developmental delay. |
from 18-26 months of age
|
|
The Bayley Scales of Infant and Toddler Development (BSID)
Time Frame: From 18-26 months of age
|
The Bayley's motor component composite score will be assessed and noted. The motor composite score is determined by comparing the child's performance to a normative age-matched sample defined by the assessment. They are interpreted as follows: Mean score of 100 (Standard deviation=15) at the 50th percentile signifies mid-average functioning. Scores below 85 (1 Standard deviation below the mean), at the 16th percentile, indicate mild impairment of being 'at risk' of developmental delay. Monitoring is recommended, along with advice to parents on techniques to enhance development or referral to a therapist based on the level of impairment. Score below 70 (2 Standard deviation below the mean), at the second percentile, indicate moderate to severe impairment. In general, scores falling in the lowest 10th percentile indicate developmental delay. |
From 18-26 months of age
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Travers CP, Carlo WA, McDonald SA, Das A, Ambalavanan N, Bell EF, Sanchez PJ, Stoll BJ, Wyckoff MH, Laptook AR, Van Meurs KP, Goldberg RN, D'Angio CT, Shankaran S, DeMauro SB, Walsh MC, Peralta-Carcelen M, Collins MV, Ball MB, Hale EC, Newman NS, Profit J, Gould JB, Lorch SA, Bann CM, Bidegain M, Higgins RD; Generic Database and Follow-up Subcommittees of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Racial/Ethnic Disparities Among Extremely Preterm Infants in the United States From 2002 to 2016. JAMA Netw Open. 2020 Jun 1;3(6):e206757. doi: 10.1001/jamanetworkopen.2020.6757.
- Santoli CMA, Taylor-Cho IA, Darling AJ, Montoya MN, Gilner JB, Wheeler SM, Dotters-Katz SK. Predictors of Breastfeeding among Patients Admitted with Preterm Prelabor Rupture of Membranes. Am J Perinatol. 2024 May;41(S 01):e3196-e3201. doi: 10.1055/a-2211-1787. Epub 2023 Nov 15.
- Quintero SM, Strassle PD, Londono Tobon A, Ponce S, Alhomsi A, Maldonado AI, Ko JS, Wilkerson MJ, Napoles AM. Race/ethnicity-specific associations between breastfeeding information source and breastfeeding rates among U.S. women. BMC Public Health. 2023 Mar 17;23(1):520. doi: 10.1186/s12889-023-15447-8.
- Huang Y, Liu Y, Yu XY, Zeng TY. The rates and factors of perceived insufficient milk supply: A systematic review. Matern Child Nutr. 2022 Jan;18(1):e13255. doi: 10.1111/mcn.13255. Epub 2021 Aug 12.
- Meek JY, Tippins S, American Academy of Pediatrics. American Academy of Pediatrics new mother's guide to breastfeeding. New York: Bantam Books; 2002. xiv, 258 p. p.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-300013718
- UAB (Other Identifier: UAB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.